Health Care·Biotechnology·$3.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.68 | N/A | +45.61% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.68 | N/A | +45.61% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting strong operational performance. They emphasized their commitment to maintaining growth.
We are pleased with our performance this quarter, especially in EPS growth.
Our focus remains on sustaining our momentum in the upcoming quarters.
Catalyst Pharmaceuticals reported a strong earnings per share, significantly beating expectations, which contributed to a 2.77% increase in stock price. The positive EPS surprise indicates effective cost management and operational efficiency. However, the lack of revenue data and future guidance leaves some uncertainty for investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DIAMONDBACK ENERGY I
Feb 23, 2026